RSV Vaccine: A Breakthrough in Protecting Infants and Expectant Mothers

Share this article

Respiratory syncytial virus (RSV) is a leading cause of respiratory illness in infants and adults ages 60 and older. As an obstetrician, I frequently meet with expectant parents who are anxious about how to protect their newborns from infections. The recent introduction of the RSV vaccine offers expectant mothers a way to safeguard their newborns from severe RSV. As a health care provider, I can help to demystify the RSV vaccine, address concerns about vaccine hesitancy, and counsel patients on the best course of action. Here are my key takeaways for health care providers speaking with patients about the RSV vaccine.

A Game-Changing Vaccine

The maternal RSV vaccine, approved for use in pregnant individuals to prevent RSV in infants, represents a significant milestone in maternal and infant health. Administered to expectant mothers between 32 and 36 weeks of gestation, it passes protective antibodies to the baby during pregnancy. Protection for the baby lasts approximately six months after birth, when infants are most vulnerable to severe infections. Two to three out of every 100 infants under 6 months are hospitalized with RSV every year; the RSV vaccine significantly reduces that risk in the first six months of life and is most effective within the first three months.

The RSV vaccine is widely available through pharmacies and in doctor’s offices. Obstetricians should talk to their patients about RSV immunization when discussing other vaccines recommended during pregnancy, such as influenza, and pertussis. As of December 7, 2024, approximately 34.5% of pregnant individuals aged 18 to 49 years and at least 32 weeks gestation had received the RSV vaccine.

Overcoming Vaccine Hesitancy

Despite clinical trials that show the benefits of the maternal RSV vaccine outweigh the risks, vaccine hesitancy remains a barrier to widespread immunization. Common concerns include the vaccine’s safety profile, potential side effects, and perceived necessity. Patient concerns should be addressed through open communication and evidence-based guidance. Clinical studies have demonstrated that the RSV vaccine is safe for administration during pregnancy, with no significant increase in adverse outcomes such as preterm birth.

1. Safety and Efficacy: Clinical trials have demonstrated that the RSV vaccine is safe for pregnant women and reduced the risk of infant hospitalization for RSV by 68%. Mild side effects, such as soreness at the injection site or fatigue, are like those of other routine vaccines.
2. Highlighting the Risk: RSV is a leading cause of bronchiolitis and pneumonia in infants, often resulting in hospitalizations. Educating patients about the prevalence and severity of RSV underscores the vaccine’s importance.
3. Understanding Misinformation: Acknowledge that misinformation about vaccines circulates widely. By providing reputable resources and fostering a space for questions, health care providers can build trust and dispel myths. Here are some resources that you can share:

• CDC Guide to RSV Immunization to Protect Infants
• American College of Obstetricians and Gynecologists Recommendations for RSV Vaccine

Counseling Patients Effectively

When discussing the RSV vaccine with patients, take a clear, empathetic, and personalized approach:

• Start with the Risk: Explain the prevalence of RSV and its potential severity, particularly in infants. Share statistics to underscore the vaccine’s role in preventing serious illness.
• Reassure them that it’s safe: Highlight that the vaccine underwent rigorous testing in pregnant women and has been endorsed by major health organizations like the American Association of Pediatricians and the American College of Obstetricians and Gynecologists.
• Emphasize the convenience: Point out that the vaccine can be conveniently administered during routine prenatal visits or independently at a local pharmacy. It does not require additional procedures or post-vaccination monitoring.
• Address Questions Openly: Encourage patients to share their concerns. Listening actively can reveal underlying fears that might be addressed with evidence-based information.

Conclusion

As an obstetrician, I am in a unique position to advocate for both maternal and infant health. The RSV vaccine is a significant breakthrough, offering a safe and effective way to protect newborns during their most vulnerable months. By addressing hesitancy with empathy and evidence-based information, we can empower expectant mothers to make informed decisions about their baby’s health.